Biogen And Eisai Announce China Approval For Subcutaneous LEQEMBI To Treat Early Alzheimer's Disease

Biogen and Eisai said China’s NMPA approved LEQEMBI (lecanemab) subcutaneous formulation as an initiation treatment for early-stage disease, expanding the drug’s use into a new, more convenient administration format. This is a meaningful regulatory win that supports potential uptake and reinforces Biogen/Eisai’s China commercial outlook. The approval could be a near-term positive catalyst for sentiment around the franchise, though the full market impact depends on uptake and commercial ramp in China.